JUNE 3
CRN is alerting members to oral comments delivered by CRN's Steve Mister and Megan Olsen at FDA's public hearing to discuss the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds on Friday, May 31.
- Oral comments delivered by CRN President and CEO Steve Mister.
- Steve Mister's Power Point presentation.
- Oral comments delivered by CRN Assistant General Counsel Megan Olsen.
CRN urged FDA to use its rulemaking authority as quickly as possible to address a market that is out of control and create a legal pathway for CBD use in supplements and food. Without FDA’s oversight, the growing CBD consumer base lacks assurance that products labeled as CBD are safe. With this, however, CRN does not believe that safety concerns have to impede rulemaking at this stage. Rather, Mr. Mister noted that while consumer safety is always the first priority of both FDA and industry, providing a predictable and lawful path to market is the first job.
Preliminary media coverage:
- Insufficient scientific research & labeling constraints could limit use of CBD in food, supplements Food Navigator
- Supplement industry to FDA on CBD regulations: “We can’t wait years” Nutritional Outlook
- CBD meeting commentary lays bare complexity of regulatory questions NutraIngredients
In addition to the comments delivered on Friday, CRN with its CBD Task Force, will submit formal written comments by the July 16 due date.
Please reach out with any questions or comments and we'll connect you with the appropriate CRN staff.
